Detalhe da pesquisa
1.
Model-based pharmacokinetic analysis of elotuzumab in patients with relapsed/refractory multiple myeloma.
J Pharmacokinet Pharmacodyn
; 43(3): 243-57, 2016 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-26993283
2.
The effects of ketoconazole and rifampin on the single-dose pharmacokinetics of crizotinib in healthy subjects.
Eur J Clin Pharmacol
; 71(12): 1441-9, 2015 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-26381275
3.
Metabolism, excretion and pharmacokinetics of [14C]crizotinib following oral administration to healthy subjects.
Xenobiotica
; 45(1): 45-59, 2015 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-25034009
4.
Model-Based Dose Selection of Subcutaneous Nivolumab in Patients with Advanced Solid Tumors.
Clin Pharmacol Ther
; 115(3): 488-497, 2024 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-38115195
5.
Model-Informed Clinical Pharmacology Profile of a Novel Fixed-Dose Combination of Nivolumab and Relatlimab in Adult and Adolescent Patients with Solid Tumors.
Clin Cancer Res
; 2024 Jan 31.
Artigo
em Inglês
| MEDLINE | ID: mdl-38295151
6.
Phase II trial of continuous once-daily dosing of sunitinib as first-line treatment in patients with metastatic renal cell carcinoma.
Cancer
; 118(5): 1252-9, 2012 Mar 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-21898376
7.
Polymeric nanoparticles for increased oral bioavailability and rapid absorption using celecoxib as a model of a low-solubility, high-permeability drug.
Pharm Res
; 29(2): 427-40, 2012 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-21863477
8.
Evaluation of Proton Pump Inhibitor Esomeprazole on Crizotinib Pharmacokinetics in Healthy Participants.
Clin Pharmacol Drug Dev
; 11(1): 34-42, 2022 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-34825782
9.
Single-Dose Pharmacokinetics of Milvexian in Participants with Normal Renal Function and Participants with Moderate or Severe Renal Impairment.
Clin Pharmacokinet
; 61(10): 1405-1416, 2022 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-35906349
10.
Exposure-Response Analysis to Support Nivolumab Once Every 4 Weeks Dosing in Combination with Cabozantinib in Renal Cell Carcinoma.
Clin Cancer Res
; 28(8): 1603-1613, 2022 04 14.
Artigo
em Inglês
| MEDLINE | ID: mdl-34980597
11.
Single-Dose Pharmacokinetics of Milvexian in Participants with Mild or Moderate Hepatic Impairment Compared with Healthy Participants.
Clin Pharmacokinet
; 61(6): 857-867, 2022 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-35262846
12.
Assessment of hyperprogression versus the natural course of disease development with nivolumab with or without ipilimumab versus placebo in phase III, randomized, controlled trials.
J Immunother Cancer
; 10(4)2022 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-35383114
13.
Collaborations between Clinical Pharmacologists in Japan and in the United States - Report from the IQ CPLG and JPMA CPTF Meeting in Tokyo, Japan.
Clin Transl Sci
; 14(1): 102-105, 2021 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-32969589
14.
Evaluation of Therapeutics for Severely Debilitating or Life-Threatening Diseases or Conditions: Defining Scope to Enable Global Guidance Development.
Clin Pharmacol Ther
; 107(3): 514-520, 2020 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-31608984
15.
A Machine-Learning Approach to Identify a Prognostic Cytokine Signature That Is Associated With Nivolumab Clearance in Patients With Advanced Melanoma.
Clin Pharmacol Ther
; 107(4): 978-987, 2020 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-31721173
16.
Estrogen suppression in premenopausal women following 8 weeks of treatment with exemestane and triptorelin versus triptorelin alone.
Breast Cancer Res Treat
; 113(3): 491-9, 2009 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-18330698
17.
Model-Based Population Pharmacokinetic Analysis of Nivolumab in Chinese Patients With Previously Treated Advanced Solid Tumors, Including Non-Small Cell Lung Cancer.
J Clin Pharmacol
; 59(10): 1415-1424, 2019 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-31115908
18.
Nivolumab Clearance Is Stationary in Patients With Resected Melanoma on Adjuvant Therapy: Implications of Disease Status on Time-Varying Clearance.
Clin Pharmacol Ther
; 106(5): 1018-1027, 2019 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-31090921
19.
Linking Tumor Growth Dynamics to Survival in Ipilimumab-Treated Patients With Advanced Melanoma Using Mixture Tumor Growth Dynamic Modeling.
CPT Pharmacometrics Syst Pharmacol
; 8(11): 825-834, 2019 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-31334596
20.
Population Pharmacokinetics and Exposure - Safety Analyses of Nivolumab in Patients With Relapsed or Refractory Classical Hodgkin Lymphoma.
J Clin Pharmacol
; 59(3): 364-373, 2019 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-30339279